HPMZ 4-Month Regimen
CDC Interim Guidance
In February 2022, CDC published Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis — United States, 2022. CDC developed the interim guidance based on evidence from Study 31, sponsored by CDC and conducted by CDC’s Tuberculosis Trials Consortium in collaboration with and the National Institutes of Health (NIH)–sponsored AIDS Clinical Trials Group (ACTG).
NSTC/NTNC Fact Sheet and FAQ
The National Society of TB Clinicians (NSTC) and National TB Nurse Coalition (NTNC) collaborated to develop guidance for providers on using the 4-month regimen of isoniazid, rifapentine, moxifloxacin, and pyrazinamide, abbreviated as HPMZ, to treat patients for pulmonary TB disease.
The guidance includes a two-page fact sheet that includes:
- A description of the length, drugs, and dosages of the HPMZ regimen
- Photos of medications
- Advantages and disadvantages of the HPMZ regimen
- Common drug-drug interactions
- Possible adverse events
- Pre-treatment patient checklist
- Baseline and follow-up monitoring and evaluation
- Programmatic considerations
For background, more detailed information, and special circumstances, there is an FAQ at that provides background on Study 31 and answers common questions about medications, monitoring, and special patient populations.
This resource is provided at no charge, but we do request that you register your download with your email address so that NTCA can track interest in the publication and alert you when updates are released.
